ORT-B Stock Analysis: Ortoma Series | ST

Medical Devices | ST, Sweden | Market Cap: 483m SEK | 12M Return: -30.7% | SE0005676103 | Charts, Fundamentals & Technical Analysis

Total Rating 13
Safety 31
Buy Signal 0.29
Medical Devices
Industry Rotation: +5.3
Market Cap: 48.5M
Avg Turnover: 115K
Risk 3d forecast
Volatility617%
VaR 5th Pctl88.8%
VaR vs Median-9.17%
Reward TTM
Sharpe Ratio-0.03
Rel. Str. IBD56.2
Rel. Str. Peer Group46.3 pctl
Character TTM
Beta0.122
Beta Downside-0.092
Hurst Exponent0.443
Choppyness40.6%
Drawdowns 3y
Max DD76.76%
CAGR/Max DD0.09
CAGR/Mean DD0.18
EPS (Earnings per Share) EPS (Earnings per Share) of ORT-B over the last years for every Quarter: "2021-09": -0.202, "2021-12": -0.0414, "2022-03": -0.1541, "2022-06": -0.1877, "2022-12": null, "2023-03": -0.1944, "2023-06": 0.3986, "2023-09": -0.0584, "2023-12": -0.7523, "2024-03": -0.1468, "2024-06": 0.1421, "2024-09": -0.0244, "2024-12": -0.2757, "2025-03": 0.4274, "2025-06": 0.033, "2025-09": -0.3818, "2025-12": -0.5816, "2026-03": -0.22, "2026-06": -0.47,
Qual. Beats: 0
Revenue Revenue of ORT-B over the last years for every Quarter: 2021-09: null, 2021-12: 0, 2022-03: null, 2022-06: null, 2022-12: 0, 2023-03: null, 2023-06: null, 2023-09: null, 2023-12: 38.140961, 2024-03: null, 2024-06: 17.511085, 2024-09: 9.910267, 2024-12: 17.253359, 2025-03: 38.716276, 2025-06: 18.793167, 2025-09: 2.42519, 2025-12: 4.7048, 2026-03: 15.787285, 2026-06: 10.424267,
Rev. CAGR: 30.18%
Rev. Trend: 100.0%
Qual. Beats: 0

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation
Overextended 3d

Tailwinds

Squeeze
Ep Pivot

Seasonality

Not enough history
Description: ORT-B Ortoma Series
Ortoma AB (publ), a medical technology company, focuses on Al-based technology for orthopedic surgical procedures in Sweden. It offers Ortoma Treatment Solution (OTS), a server-based AI integrated orthopedic platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and post-operative follow-up; and OTS Guide, an intra-operative navigation tool guiding surgeons to place the implant in the pre-operatively planned position. The company was founded in 2001 and is based in Gothenburg, Sweden.
Headlines to Watch Out For
Piotroski VR-10 (Strict) 0.5
Net Income: -65.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA -38.79 > 1.0
NWC/Revenue: 180.3% < 20% (prev 64.62%; Δ 115.7% < -1%)
CFO/TA -0.24 > 3% & CFO -46.7m > Net Income -65.9m
Net Debt/EBITDA: error (cannot be calculated)
Current Ratio: 3.72 > 1.5 & < 3
Outstanding Shares: last quarter (46.8m) vs 12m ago 23.74% < -2%
Gross Margin: 38.11% > 18% (prev 87.53%; Δ -49.42% > 0.5%)
Asset Turnover: 17.01% > 50% (prev 43.23%; Δ -26.22% > 0%)
Interest Coverage Ratio: -593.0 > 6 (EBIT TTM -65.8m / Interest Expense TTM 111k)
Altman Z'' 3.50
A: 0.31 (Total Current Assets 82.2m - Total Current Liabilities 22.1m) / Total Assets 196.2m
B: -1.39 (Retained Earnings -272.4m / Total Assets 196.2m)
C: -0.34 (EBIT TTM -65.8m / Avg Total Assets 196.1m)
D: 7.88 (Book Value of Equity 174.1m / Total Liabilities 22.1m)
Altman-Z'' = 3.50 = A
Beneish M -0.71
DSRI: 3.0 (Receivables 6.47m/2.26m, Revenue 33.3m/84.7m)
GMI: 2.30 (GM 87.53% / 38.11%)
AQI: 0.90 (AQ_t 0.58 / AQ_t-1 0.64)
SGI: 0.39 (Revenue 33.3m / 84.7m)
TATA: -0.10 (NI -65.9m - CFO -46.7m) / TA 196.2m)
Beneish M = -0.71 (Cap -4..+1) = D
What is the price of ORT-B shares?

As of October 28, 2026, the stock is trading at SEK 11.26 with a total of 1,222,157 shares traded. Over the past week, the price has changed by +57.48%, over one month by +48.75%, over three months by +25.81% and over the past year by -30.71%.

Current recommended Stop Loss: 10.90 (which is 3.2% or 1.4 ATR below the current price).

Is ORT-B a buy, sell or hold?

Ortoma Series has no consensus analysts rating.

Ortoma Series (ORT-B) - Fundamental Data Overview as of 28 October 2026
Market Cap USD = 48.5m (482.8m SEK * 0.1005 SEK.USD)
P/S = 14.2409
P/B = 1.9318
Revenue TTM = 33.3m SEK
EBIT TTM = -65.8m SEK
EBITDA TTM = -54.2m SEK
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = unknown
 Net Debt = unknown
 Enterprise Value = 420.1m SEK (482.8m + (null Debt) - CCE 62.7m)
Interest Coverage Ratio = -593.0 (Ebit TTM -65.8m / Interest Expense TTM 111k)
EV/FCF = -8.81x (Enterprise Value 420.1m / FCF TTM -47.7m)
FCF Yield = -11.35% (FCF TTM -47.7m / Enterprise Value 420.1m)
 FCF Margin = -143.1% (FCF TTM -47.7m / Revenue TTM 33.3m)
 Net Margin = -197.7% (Net Income TTM -65.9m / Revenue TTM 33.3m)
Gross Margin = 38.11% ((Revenue TTM 33.3m - Cost of Revenue TTM 20.6m) / Revenue TTM)
Gross Margin QoQ = 17.20% (prev 64.37%)
Tobins Q-Ratio = 2.14 (Enterprise Value 420.1m / Total Assets 196.2m)
 Interest Expense / Debt = unknown (Interest Expense 111k / Debt none)
 Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -49.4m (EBIT -65.8m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 3.72 (Total Current Assets 82.2m / Total Current Liabilities 22.1m)
 Debt / Equity = unknown (Debt none)
 Debt / EBITDA = unknown (Net Debt none / EBITDA -54.2m)
 Debt / FCF = unknown (Net Debt none / FCF TTM -47.7m)
 Total Stockholder Equity = 158.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.63% (Net Income -65.9m / Total Assets 196.2m)
RoE = -41.70% (Net Income TTM -65.9m / Total Stockholder Equity 158.1m)
RoCE = -37.80% (EBIT -65.8m / Capital Employed (Total Assets 196.2m - Current Liab 22.1m))
 RoIC = -28.62% (negative operating profit) (NOPAT -49.4m / Invested Capital 172.5m)
 WACC = 6.06% (E(482.8m)/V(482.8m) * Re(6.06%) + (debt-free company))
Discount Rate = 6.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.13 | Cagr: 12.32%
 [DCF] Fair Price = unknown (Cash Flow -47.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.97 | Revenue CAGR: 30.18% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-1.09 | Chg30d=N/A | Revisions=-25% | GrowthEPS=-109.6% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=-0.62 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+43.1% | GrowthRev=+65.7%